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Abstract 1 
Objective Developing a small animal model that accurately delineates the natural 2 
history of hepatitis B virus (HBV) infection and immunopathophysiology is necessary 3 
to clarify the mechanisms of host-virus interactions and to identify intervention 4 
strategies for HBV-related liver diseases. This study aimed to develop an 5 
HBV-induced chronic hepatitis and cirrhosis mouse model through transplantation of 6 
human bone marrow mesenchymal stem cells (hBMSCs). 7 
Design Transplantation of hBMSCs into Fah-/-Rag2-/-IL-2Rγc-/- SCID (FRGS) mice 8 
with fulminant hepatic failure (FHF) induced by hamster-anti-mouse CD95 antibody 9 
JO2 generated a liver and immune cell dual-humanized (hBMSC-FRGS) mouse. The 10 
generated hBMSC-FRGS mice were subjected to assessments of sustained viremia, 11 
specific immune and inflammatory responses and liver pathophysiological injury to 12 
characterize the progression of chronic hepatitis and cirrhosis after HBV infection. 13 
Results The implantation of hBMSCs rescued FHF mice, as demonstrated by robust 14 
proliferation and transdifferentiation of functional human hepatocytes and multiple 15 
immune cell lineages, including B cells, T cells, NK cells, dendritic cells (DCs) and 16 
macrophages. After HBV infection, the hBMSC-FRGS mice developed sustained 17 
viremia and specific immune and inflammatory responses and showed progression to 18 
chronic hepatitis and liver cirrhosis at a frequency of 55% after 54 weeks. 19 
Conclusion This new humanized mouse model recapitulates the liver cirrhosis 20 
induced by human HBV infection, thus providing research opportunities for 21 
understanding viral immune pathophysiology and testing antiviral therapies in vivo. 22 
 23 
Key words: stem cell; humanized mice; hepatitis B virus; chronic hepatitis and cirrhosis 24 
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Significance of this study 1 
What is already known on this subject? 2 
 Host immune and inflammatory responses are critical in HBV infection and 3 
progression to end-stage liver cirrhosis, but the mechanism remains unclear, and 4 
there is currently no cure for chronic HBV infection. 5 
 Few liver and immune system dual-humanized mouse models generated by the 6 
co-transplantation of human haematopoietic stem cells and hepatocytes can 7 
mimic HBV viremia, but the long-term progression of HBV-induced liver 8 
cirrhosis has not been obviously observed. 9 
 Implanted hBMSCs in FHF animal can efficiently proliferate and 10 
transdifferentiate into functional hepatocytes, and such cells may be susceptible 11 
to HBV infection. However, whether implanted hBMSCs are capable of 12 
differentiation into syngeneic immune cells for responding against HBV needs to 13 
be clarified.  14 
What are the new findings? 15 
 A new liver and immune system dual-humanized “hBMSC-FRGS” mouse model 16 
was developed in mice with fulminant hepatic failure through a single 17 
transplantation of hBMSCs. 18 
 The hBMSCs implanted through one splenic injection of hBMSCs 19 
transdifferentiated into functional human hepatocytes and multiple immune cell 20 
lineages including B cells, T cells, NK cells, dendritic cells and macrophages. 21 
 The dual-humanized hBMSC-FRGS mice were sensitive to chronic HBV 22 
infection, generated sustained human immune and inflammatory responses and 23 
ultimately developed liver cirrhosis. 24 
How might it impact on clinical practice in the foreseeable future? 25 
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 The hBMSC-FRGS mice provide a novel platform for observing host-virus 1 
interactions and the progression of HBV-induced hepatitis and liver cirrhosis, 2 
which might be helpful for the development of novel antivirals and therapeutic 3 
strategies for HBV-related liver diseases. 4 
 With further improvement and investigation, this liver and immune system 5 
dual-humanized mouse model might become useful for studying human immunity 6 
against HBV-related liver diseases. 7 
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Introduction 1 
HBV infection, which has a complicated progressive course, is a serious public health 2 
problem throughout the world and greatly increases the risk for liver cirrhosis [1, 2]. 3 
Immune and inflammatory responses are critical in HBV infection and progression to 4 
chronic liver diseases. In the past few years, several animal models (woodchucks, 5 
tupaia and human liver chimeric mouse) have been developed for modelling HBV 6 
infection, but these animals do not exhibit the full immune response spectrum due to 7 
the very narrow host range of HBV [3, 4, 5, 6]. Although chimpanzees are fully 8 
permissive for HBV infection, the strong ethical restrictions severely limit their use 9 
for research purposes. Therefore, the development of an adequate liver and immune 10 
system dual humanized animal model that accurately delineates the natural history of 11 
HBV infection and immunopathophysiology is necessary for identifying strategies for 12 
early intervention and antiviral therapy. Four mouse models were recently developed 13 
through the co-transplantation of human foetal hepatocytes and syngeneic CD34+ 14 
haematopoietic stem cells (HSCs) or miss-matched human adult hepatocytes and HSCs, 15 
and these models were permissive to HBV or hepatitis C virus (HCV) infection and 16 
generated a mild immune response against the virus [7, 8, 9, 10], but complete HBV or 17 
HCV disease progression to end-stage liver diseases has not been observed. Further 18 
translation is also critically limited by ethical issues and a shortage of available foetal 19 
donor hepatocytes with syngeneic HSCs. 20 
 21 
As many studies have indicated, human bone marrow mesenchymal stem cells 22 
(hBMSCs) are easily isolated and differentiated into hepatocytes in vitro and in vivo 23 
[11, 12, 13]. Our previous studies demonstrated that, hBMSC transplantation rescued 24 
FHF in pigs and there were no immunological rejections occurred. The implanted 25 
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hBMSCs efficiently proliferated and transdifferentiated into functional hepatocytes, 1 
and the recipient responses to liver damage were altered by immune regulation 2 
through paracrine effects [14, 15]. Other studies have also indicated that human 3 
mesenchymal stem cells are capable of differentiating into HSCs [16, 17, 18, 19]. 4 
These results imply that hBMSC-derived hepatocytes (hBMSC-Heps) in animals 5 
might be susceptible to HBV infection and that human immune responses against 6 
HBV might be activated by hBMSC-derived syngeneic immune cells. 7 
 8 
In this study, we first set out to develop a liver and immune system dual humanized 9 
FRGS mouse model through hBMSC transplantation to delineate the natural course of 10 
HBV infection and disease progression (Figure 1A, left). These animals, which we 11 
refer to as ‘hBMSC-FRGS’ mice, showed stable chimerism of hBMSC-Heps and 12 
syngeneic immune cell lineages and displayed a chronic HBV infection course similar 13 
to that observed in chronic HBV-infected (CHB) patients. Following HBV infection, 14 
we observed the full viral life cycle, including the production of HBV DNA, covalently 15 
closed circular DNA (cccDNA), surface antigen (HBsAg), e antigen (HBeAg), core 16 
antigen (HBcAg), and HBV-induced human immune and inflammatory responses and 17 
a subsequent progression to liver cirrhosis (Figure 1A, right). 18 
 19 
Materials and methods 20 
Isolation, culture and identification of hBMSCs 21 
The hBMSCs were isolated through bone marrow aspiration from the iliac crest of 22 
healthy male volunteers. More details regarding the methods used for hBMSC 23 
isolation, culture, phenotypic identification and multi-lineage differentiation are 24 
provided in Figure S1 and the Supplementary Materials and Methods. Cells from 25 
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passages 3-7 were used for the experiments. 1 
 2 
Generation of hBMSC-FRGS mice through the transplantation of hBMSCs into 3 
FRGS mice with life-threatening FHF 4 
Fah-/-Rag2-/-IL-2Rγc-/- (FRG) mice were bred with BALB/c SCID mice to obtain FRGS 5 
mice. All the mice were bred in a specific pathogen-free (SPF) laboratory in the Animal 6 
Centre of Xiamen University. All the animal experiments were approved by the Ethics 7 
Committee of the State Key Laboratory of Molecular Vaccinology and Molecular 8 
Diagnostics and the National Institute of Diagnostics and Vaccine Development in 9 
Infectious Diseases of Xiamen University.  10 
 11 
To enhance robust expansion of human-derived cells, life-threatening liver failure was 12 
induced by administration of the mouse hepatocyte-specific hepatotoxic 13 
hamster-anti-mouse CD95 antibody clone JO2 (JO2) and gradient 14 
2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) withdrawal during 15 
the perioperative period [8, 20]. FRGS mice at 6-8 weeks of age were subjected to 16 
gradient NTBC withdrawal through their drinking water from day -14 to -8 and 17 
administered 100% NTBC from day 7 to 10 and an intraperitoneal JO2 injection (0.2 18 
mg/kg) at days -1, 2, 5 and 8. To further eliminate murine immune cells and guarantee 19 
robust expansion of human immune cells, the mice received an intraperitoneal injection 20 
(25 mg/kg) of busulfan (dissolved in DMSO and diluted with 0.9% saline) at days -7, 21 
-3 and -1 [8]. For hBMSC transplantation, the FHF-FRGS mice received an 22 
intrasplenic injection of 1×106 hBMSCs suspended in 0.4 mL of normal saline at day 0, 23 
and other FHF-FRGS mice received the same treatment without cell transplantation. 24 
The mice belonging to the normal FRGS group mice only received 100% NTBC in 25 
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their drinking water (Figure 1B). Animal surgery was performed under sterilized 1 
conditions and anaesthesia with isoflurane. To promote further expansion of 2 
hBMSC-Heps, the mice were cycled off NTBC every two weeks after one week 3 
following transplantation. To maintain the liver chimerism of hBMSC-Heps, the mice 4 
received persistent NTBC addition to their drinking water starting at week 10 after 5 
transplantation. Liver repair and regeneration by the transplanted hBMSCs were 6 
demonstrated by haematoxylin and eosin (H&E) staining of liver tissues and 7 
biochemical analyses of liver function-related markers. 8 
 9 
Identification of the chimerism of hBMSC-Heps and hBMSC-derived immune cell 10 
lineages in hBMSC-FRGS mice 11 
The chimerism of hBMSC-Heps was assessed by measuring the human albumin 12 
(hALB) levels in serum through a fluorescent-activated cell sorting (FACS) analysis 13 
of total liver cells isolated by collagenase perfusion. The isolated hBMSC-Heps and 14 
mouse livers were subjected to immunohistochemistry (IHC) and quantitative reverse 15 
transcription polymerase chain reaction (qRT-PCR) assays for the analysis of human 16 
hepatocyte-specific markers and genes. The serum hALB levels were measured by 17 
enzyme-linked immunosorbent assay (ELISA). The chimeric rates of hBMSC-Heps 18 
were evaluated by the linear relationship between the percentage of hALB+/human 19 
sodium-sodium taurocholate co-transporting polypeptide positive (hNTCP+) cells in 20 
perfused liver cells and the serum hALB levels. To identify the chimerism of 21 
hBMSC-derived immune cell lineages, bone marrow (BM), lymph node, peripheral 22 
blood, spleen and liver non-parenchymal cells were collected and analysed by FACS 23 
using human leukocyte markers as previously described [9, 21, 22].  24 
The hBMSC-derived human immune cell lineages in liver tissues were identified by 25 
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IHC and IF staining. The functions of the hCD45+ cells isolated from the livers of 1 
hBMSC-FRGS mice were assessed by ELISAs of human cytokines after in vitro 2 
stimulation of phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate 3 
(PMA)/ionomycin. More details regarding the methods used for cell isolation, 4 
stimulation, FACS, ELISA, IHC, IF and qRT-PCR are provided in Figure S2 and in 5 
the Supplementary Materials and Methods section.  6 
 7 
Establishment and characterization of HBV infection in hBMSC-FRGS mice 8 
The four common HBV genotypes, namely, A, B, C and D, which have been 9 
recognized as highly epidemic HBV strains worldwide, were investigated. Because of 10 
its tendency to induce epidemics in Asia and its high pathogenicity, HBV genotype C 11 
is typically used for the long-term observation of HBV-induced liver diseases. The 12 
serum and intracellular HBV DNA levels were analysed using HBV X protein-specific 13 
probes and measured by qRT-PCR. The distributions of HBsAg+ and HBcAg+ cells 14 
were detected by IHC staining. The proportion of HBsAg+ cells in the population of 15 
hALB+ cells was analysed through cell counting of IHC results. The ratio of HBV 16 
DNA-positive cells in hALB+ cells was detected by fluorescence in situ hybridization 17 
(FISH). The intracellular HBV cccDNA levels were measured by southern blot and 18 
qRT-PCR. Details of the procedures used for HBV inoculation and virological 19 
measurements are provided in the Supplementary Materials and Methods section and 20 
in our previous publications [23, 24].  21 
 22 
Observations of immune and inflammatory responses, chronic hepatitis and liver 23 
cirrhosis 24 
Liver cells of uninfected controls and HBV-infected hBMSC-FRGS mice were isolated 25 
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by collagenase perfusion, and the cellularity of intrahepatic human immune cells was 1 
analysed by FACS. The levels of serum cytokines and HBV-specific antibodies were 2 
measured using corresponding ELISA kits. The expression of human cytokine-relevant 3 
genes in liver tissues was assessed by qRT-PCR. For observations of immune cell 4 
recruitment and chronic liver inflammation, paraffin and frozen sections of the 5 
indicated liver tissues were subjected to immunostaining and H&E staining.  6 
 7 
The levels of the cirrhosis markers hyaluronic acid (HA) and gamma glutamate 8 
transpeptidase (GGT) in the mice serum were measured by ELISA. The expression of 9 
cirrhotic-relevant human genes in liver tissues was detected by qRT-PCR. For 10 
observations of pathological features and the progression of liver cirrhosis, paraffin 11 
sections collected from the indicated liver tissues were subjected to IHC and 12 
pathological staining analyses, which included H&E, Masson’s trichrome (M&T), 13 
Van Gieson (V.G.) and Sirius red/Fast green (SR/FG) staining. Pathological analysis 14 
and progression of liver fibrosis to cirrhosis were diagnosed according to Bulletin of 15 
the World Health Organization “The morphology of cirrhosis: definition, 16 
nomenclature, and classification” [25, 26] by a pathologist with more than 10 year 17 
experience. Detailed criteria of liver fibrosis and cirrhosis are available in 18 
supplementary materials. 19 
 20 
Statistics 21 
The results of the measurements are presented as the means±SEMs. No statistical 22 
method was used to predetermine sample sizes. For comparisons between two groups, 23 
unpaired Welch’s t test was applied for calculating statistical probability in this study. 24 
For comparisons between more than two groups, one-way ANOVA followed by 25 
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Tukey’s post hoc test was applied. Statistical analysis was performed using Prism 7 1 
(GraphPad, La Jolla, CA, USA).  2 
 3 
More methodological details are provided in the Supplementary Materials and 4 
Methods section and in Supplementary Tables 1 (reagents), 2 (Antibodies) and 3 5 
(Primers). 6 
 7 
 8 
 9 
RESULTS 10 
Human BMSC transplantation rescued FHF mice 11 
The hBMSCs used in this study possessed typical mesenchymal stem cell phenotypes 12 
(positive for hCD90 and hCD29 but negative for hCD34 and hCD45) and 13 
multi-potential differentiation characteristics (differentiate to adipocytes, osteocytes 14 
and hepatocyte-like cells in vitro), which were isolated from donor iliac crest (Figure 15 
S1). The FHF mouse model was induced by gradient withdrawal of NTBC and 16 
multiple injections of JO2 (for details, see Figure 1B). The transplantation group mice 17 
received an intrasplenic injection of 1×106 hBMSCs, and the FHF-FRGS mice 18 
underwent a sham operation and received normal saline without cells. NTBC was 19 
added daily to the drinking water of normal FRGS mice (Figure 1B). The analysis of 20 
survival during the perioperative period revealed that all the FHF-FRGS mice died 21 
within four days, and the implanted hBMSCs rescued 86.7% (26/30) of the mice from 22 
life-threatening FHF (Figure 1C, top). The long-term survival observations revealed 23 
that 27 of 30 normal FRGS mice (90%) and 22 of 26 hBMSC-FRGS mice (84.6%) 24 
survived for more than 60 weeks (Figure 1C, bottom). A biochemical analysis of eight 25 
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representative liver and functional biomarkers, including alanine transaminase (ALT), 1 
aspartate aminotransferase (AST), total bilirubin (TB), total bile acid (TBA), total 2 
cholesterol (TC), blood urea nitrogen (BUN), total protein (TP) and prothrombin time 3 
(PT), showed that hBMSC transplantation significantly improved liver function 4 
(Figure 1D). H&E staining further confirmed that the hBMSC transplantation was 5 
notably coupled with repair of the damaged liver structure at day7, whereas the 6 
deceased FHF-FRGS mice showed the typical histology of a failed liver with extensive 7 
hepatic necrosis and haemorrhage at day 3 after transplantation (Figure 1E). These 8 
results indicated that, hBMSC transplantation rescued FHF-FRGS mice within the first 9 
week after the initial JO2 injection.  10 
 11 
Chimerism of hBMSC-derived human hepatocytes in hBMSC-FRGS mice  12 
Mouse serum, perfused liver cells and liver tissues were collected to investigate the 13 
chimerism of hBMSC-Heps. hALB was detectable in the mice serum at week 3, 14 
increased to 1.72±0.07 mg/mL at week 12 and remained at 1.60±0.13 mg/mL at week 15 
60 after hBMSC transplantation (Figure 2A). FACS showed that human leukocyte 16 
antigen (HLA)-positive cells were detectable in the entire population of mouse liver 17 
cells (10.2±0.7%) at week three, increased to 45.8±1.5% at week 12 and remained at 18 
42.4±1.0% at week 60 after transplantation (Figure 2B). Further analysis showed that 19 
91.7±1.0%, 90.2±1.5%, and 1.8±0.4% of HLA+ cells were positive for hALB, HBV 20 
receptor hNTCP and hCD45, respectively, at week 12 after hBMSC transplantation, 21 
and these levels were maintained until week 60 (Figure 2B). A correlation analysis 22 
between the percentages of hNTCP+ cells in the whole population of mouse liver cells 23 
with the serum hALB concentrations revealed that, the average human hepatocyte 24 
chimerism reached 47.2±2.5% at week 12 after transplantation and that this level was 25 
  16 / 47 
 
maintained until week 60 after transplantation (Figure 2C).  1 
 2 
The phase-contrast microscopy image showed hALB+ hBMSC-Heps freshly isolated 3 
by FACS with a typical hepatocyte morphology in vitro (Figure 2D). IF staining 4 
showed over 90% of hALB+ hBMSC-Heps were also positive for hNTCP (Figure 2E). 5 
The qRT-PCR results showed that hALB+ hBMSC-Heps isolated from hBMSC-FRGS 6 
mice stably expressed 19 human hepatocyte-specific genes from 12 to 60 weeks after 7 
transplantation (Figure 2F). IHC staining of serial sections showed that the HLA+ cells 8 
were also positive for human hepatocyte-specific markers hALB, fumarate 9 
dehydrogenase (hFAH), alpha-1-antitrypsin (hAAT), cytokeratin 18 (hCK18) and 10 
hNTCP (Figure 2G). The whole liver lobe showed 58.7% chimerism of hALB+ cells 11 
and multiple distribution patterns (Figure 2H). Additionally, no cell fusion between 12 
human-derived hepatocytes and mouse hepatocytes was observed in hBMSC-FRGS 13 
mice (Figure S3). Taken together, these results indicated the stable chimerism of 14 
hBMSC-Heps in hBMSC-FRGS mouse livers. A preliminary tumourigenicity assay 15 
revealed that, the surviving hBMSC-FRGS mice showed no evidence of tumours in the 16 
liver or other organs (including the brain, heart, lung, kidney, spleen, small gut and 17 
muscles) from week 0 to 60 after transplantation, as demonstrated by an analysis of 18 
human hepatocellular carcinoma specific markers in serum and liver tissue combined 19 
with H&E staining analysis (Figure S4). The above results indicated that hBMSC 20 
transplantation resulted in the generation of a humanized liver mouse model. 21 
 22 
Chimerism of hBMSC-derived human immune cell lineages in hBMSC-FRGS 23 
mice  24 
FACS results showed that the BM, thymus, lymph node, spleen, liver and peripheral 25 
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blood of hBMSC-FRGS mice were reconstituted with varying amounts of hCD45+ 1 
cells at week 12 after transplantation (Figure 3A, blue circle), whereas these cells 2 
were undetectable in the control FRGS mice (Figure 3A, black circle). Further 3 
functional analysis of in vitro cultured hCD45+ cells enriched from the livers of 4 
hBMSC-FRGS mice had detectable levels of seven human-derived inflammatory 5 
cytokines (hTNF-α, hIFN-α, hIFN-γ, hIL-2, hIL-6, hIL-8 and hIL-10) 24 hours after 6 
stimulation with PHA and PMA/ionomycin (Figure 3B). Unstimulated hCD45+ cells, 7 
which were used as controls, showed very low levels of these cytokines (Figure 3B). 8 
An IHC analysis showed that human-derived immune cells (hCD45+), including 9 
human B cells (hCD19+), T cells (hCD4+ and hCD8+), NK cells (hNKp46+), 10 
macrophages (hCD86+ and hCD163+) and dendritic cells (hCD11c+ and hCD123+) 11 
were scattered in the liver tissue of hBMSC-FRGS mice at 12 weeks after 12 
transplantation (Figure 3C).  13 
 14 
Multiple human immune cell lineages derived from 10 different hBMSCs donors in 15 
the peripheral blood, spleen and liver of hBMSC-FRGS mice were subsequently 16 
assessed by FACS. The gating scheme and representative FACS plots of multiple 17 
human immune cell lineages in the livers of hBMSC-FRGS mice were displayed in 18 
Figure 3D. The analysis of hBMSC-derived human immune cell lineages from 10 19 
different donors (n=3/donor) at week 12 after transplantation revealed that hCD45+ 20 
cells constituted 34.5±3.3%, 30.6±2.7% and 45.2±2.9% of the total CD45+ (mCD45 21 
and hCD45) cells in the peripheral blood, spleen and liver, respectively (Figure 3E, 22 
line 1), and 27.0±2.4%, 29.5±2.6% and 33.6±2.3% of the total hCD45+ cells in the 23 
peripheral blood, spleen and liver, respectively, were hCD19+ B cells (Figure 3E, line 2). 24 
In addition, hCD3+ T cells constituted 27.4±1.6%, 26.1±2.2% and 24.1±2.4% of the 25 
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total population of hCD45+ cells in the peripheral blood, spleen and liver, respectively 1 
(Figure 3E, line 3), and 4.1±0.3%, 4.2±0.3% and 3.9±0.4% of the total hCD45+ cells in 2 
the peripheral blood, spleen and liver, respectively, were hCD3-hNKp46+ NK cells 3 
(Figure 3E, line 4). hCD3-hCD14+hCD68+ macrophages constituted 9.7±0.7%, 4 
11.8±0.2% and 12.9±0.2% of the total hCD45+ cell population in the peripheral blood, 5 
spleen and liver, respectively (Figure S5A). Moreover, hCD3-hCD14-HLA-DR+ DCs 6 
comprised 4.2±0.3%, 4.9±0.2% and 5.4±0.2% of the total hCD45+ cells in the 7 
peripheral blood, spleen and liver, respectively (Figure S5B). These hBMSC-derived 8 
human immune cell lineages were maintained at comparable frequencies in the blood, 9 
spleen and liver until week 60 after transplantation (Figure 3E and Figure S5). 10 
 11 
Analysis of T cells revealed that, the hCD3+ T cells in the spleen and liver exhibited a 12 
high hCD4/hCD8 ratio (with the majority of these cells being hCD4+ T cells) at both 13 
week 12 and 60 after transplantation (Figure 3F). As demonstrated through an analysis 14 
of macrophages, 58.6±5.5% and 50.2±5.1% of the macrophage populations in the liver 15 
and spleen at week 12, respectively, were CD163+ M2 macrophages, 32.1±3.6% and 16 
39.5±5.8% of these populations, respectively, were hCD86+ M1 macrophages, and 17 
these levels were maintained until week 60 after transplantation (Figure 3G). An 18 
analysis of DCs showed that 71.1±4.9% and 74.2±3.2% of the DCs in the spleen and 19 
liver at week 12, respectively, were CD11c+ myeloid DCs, 18.2±4.4% and 19.9±1.8% 20 
of these populations, respectively, were hCD123+ plasmacytoid DC subset, and these 21 
levels were maintained until 60 after transplantation (Figure 3H). These results 22 
demonstrated that a humanized immune cell mouse model with syngeneic human 23 
hepatocytes was developed.  24 
 25 
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hBMSC-FRGS mice support sustained HBV infection 1 
To test the ability of hBMSC-Heps to support HBV infection, different single 2 
donor-derived hBMSC-FRGS mice exhibiting 40-60% chimerism of human liver cells 3 
were infected with HBV genotype C. The serum hALB levels were maintained at 4 
1.5-2.5 mg/mL throughout the infection course, and at 16 weeks post-infection (w.p.i.), 5 
the HBV DNA, HBsAg and HBeAg levels were increased to 107-109 copies/mL (Figure 6 
4A), 103-104 IU/mL, and 30-40 PEIU/mL, respectively (Figure 4B). Serum HBV DNA 7 
and antigens were maintained at these high levels until 56 w.p.i. in HBV-infected 8 
hBMSC-FRGS mice (Figures 4A and 4B) and were undetectable in the uninfected 9 
controls (Figure S6A and S6B). 10 
 11 
To visualize the HBV distribution in the chimeric liver, liver tissues collected from the 12 
HBV-infected hBMSC-FRGS mice from 0 to 56 w.p.i. were subjected to IHC for the 13 
human liver protein hALB and HBV antigens. FRGS mice without transplantation 14 
and uninfected hBMSC-FRGS mice were used as controls. As shown by serial 15 
sections obtained from HBV-infected hBMSC-FRGS mice at 16 w.p.i., more than 80% 16 
of hALB-positive liver cells were co-positive for HBsAg and HBcAg (Figure 4C), 17 
and the distribution and proportion of HBsAg-positive (HBsAg+) cells in 18 
hALB-positive (hALB+) liver cells varied over time. A statistical analysis of the IHC 19 
staining results from different fields of view showed that, the percentages of HBsAg+ 20 
cells in the population of hALB+ cells were 25.7±3.2% at 4 w.p.i., 54.1±5.1% at 8 21 
w.p.i., 85.2±3.4% at 16 w.p.i., 78.1±4.4% at 32 w.p.i. and 73.4±5.2% at 56 w.p.i. 22 
(Figure 4D). A FISH analysis showed that hBMSC-Heps isolated from HBV-infected 23 
hBMSC-FRGS mice were positive for HBV DNA at 4 w.p.i. (Figure 4E). The 24 
quantitative results of a southern blot analysis showed that intrahepatic HBV cccDNA 25 
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was detectable in hBMSC-FRGS mice with chronic HBV infection (Figures 4F and 1 
4G). A regression analysis revealed a positive relationship among serum HBV DNA, 2 
serum HBsAg and intracellular HBV cccDNA (Figure 4H). In addition, 3 
hBMSC-FRGS mice with comparable chimerism of human liver cells were also 4 
permissive for sustained infection with HBV genotypes A, B and D and showed 5 
similar trends in their serum HBV DNA, HBsAg and HBeAg levels (Figure S7). 6 
These results demonstrated the establishment of sustained HBV infection in 7 
hBMSC-FRGS mice. 8 
 9 
Human-derived immune and inflammation responses and chronic hepatitis 10 
developed spontaneously after HBV infection in hBMSC-FRGS mice 11 
To assess the cellular immune responses against HBV infection in hBMSC-FRGS 12 
mice, liver cells were perfused from 0 to 48 w.p.i. and analysed by FACS. The amount 13 
of intrahepatic hCD45+ cells significantly increased following HBV infection (Figure 14 
5A, top left). HBV-infected hBMSC-FRGS mice exhibited a 3.2-fold increase in 15 
intrahepatic hCD45+hCD3-hNKp46+ NK cell frequencies at 12 w.p.i., and these levels 16 
were reduced to the normal levels at 24 w.p.i. (Figure 5A, top right). The frequencies 17 
of intrahepatic hCD45+hCD3-hCD68+ macrophages and hCD45+hCD3+ T cells 18 
showed gradual increases to levels that were 4.4-fold and 2.5-fold higher than the 19 
baseline levels at 24 w.p.i., respectively, and these increased levels were maintained 20 
until 48 w.p.i. (Figure 5A, bottom). Furthermore, IF of the livers from HBV-infected 21 
hBMSC-FRGS mice revealed abundant hCD68+ macrophages throughout the liver 22 
parenchyma and intertwined between HBsAg+ hepatocytes (Figure 5B).  23 
 24 
The presence of human-derived cytokines, which are important mediators in liver 25 
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immunopathologic injury during sustained HBV infection, in hBMSC-FRGS mice was 1 
detected by ELISA, and the results showed a persistent release of four types of 2 
cytokines into serum from 2 to 48 w.p.i. In contrast to the uninfected controls, the 3 
HBV-infected mice had significantly increased levels of the inflammatory mediators’ 4 
hIL-6 and hIL-17 and of the immunosuppressive factors hIL-4 and hIL-10 from 2 to 48 5 
w.p.i. (Figure 5C). The levels of the chemotactic factors hIL-8 and hCXCL10, as well 6 
as hIFN-α and hIFN-γ, were increased from 2 to 24 w.p.i., and this trend was 7 
maintained throughout the same course of infection (Figure 5C). The 8 
immunosuppressive factors hIL-23, hIL-27, hIL-2, hIL-32 and hTNF-α, the 9 
immunosuppressive factors hIL-1ra and hIL-13, chemotactic factor hCXCL9, and 10 
hIFN-β also showed a similar slight increase during the same infection course (Figure 11 
S8A). qRT-PCR results further confirmed similar trends for these human 12 
inflammatory-related cytokine genes in liver tissues collected from HBV-infected 13 
hBMSC-FRGS mice during the same infection course (Figure 5D and Figure S9B). 14 
HBV-infected mice showed a significant increase in the human-derived IgM serum 15 
levels and a mild increment in the hIgG levels (Figure 5E). ELISAs for HBV antibodies 16 
revealed that, the serum concentrations of HBsAg antibody (HBsAb), HBeAg antibody 17 
(HBeAb), and HBcAg antibody (HBcAb) increased to 53.6±18.9 ng/mL, 146.2±15.4 18 
ng/mL and 46.2±15.4 ng/mL at 12 to 16 w.p.i, respectively, and these levels were 19 
maintained until week 32 w.p.i. and then gradually decreased (Figure 5F). The 20 
serological changes in hIgM, hIgG, HBsAb, HBeAb and HBcAb in individual animals 21 
were presented in Figure S8C and S8D. Furthermore, the majority of HBsAb and 22 
HBcAb were IgM, rather than IgG at 24 w.p.i. (Figure S8E). 23 
 24 
Observations of the pathological changes in the liver during the HBV infection course, 25 
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as demonstrated though H&E staining, showed an acute hepatitis pattern with 1 
significant lobular inflammation, lymphoid aggregates and duct lesions at 12 w.p.i. 2 
Chronic hepatitis patterns with varying degrees of predominantly lymphocytic portal 3 
inflammation and interface hepatitis were observed in hBMSC-FRGS mice at 24 4 
w.p.i., whereas the liver tissues collected from uninfected hBMSC-FRGS mice 5 
showed no pathological changes during this period (Figure 5G). Furthermore, eight 6 
representative liver functional biomarkers in the serum revealed liver injury in 7 
HBV-infected hBMSC-FRGS mice (Figure S8F). These results showed that 8 
hBMSC-FRGS mice displayed the typical immunopathology characteristics observed 9 
during the course of chronic HBV infection, which indicated that, these mice exhibited 10 
a chronic hepatitis pattern similar to the one observed in CHB patients. 11 
 12 
Progression of liver cirrhosis in HBV-infected hBMSC-FRGS mice 13 
Serological and histological analyses were performed to determine HBV-induced liver 14 
cirrhosis in hBMSC-FRGS mice. The detection of serological cirrhotic markers 15 
showed that, the HA and GGT levels were significantly increased from 18 to 54 w.p.i. 16 
(Figure 6A, red line), and qRT-PCR indicated that four human fibrosis-relevant genes 17 
(hCOL1A1, hCOL1A2, hTIMP-1 and hMMP-2) were significantly and simultaneously 18 
elevated (Figure 6B, red column).  19 
 20 
Preliminary observations revealed that, the gross appearance of a normal liver is 21 
reddish brown in colour and has a soft consistency and smooth surface, whereas the 22 
cirrhotic liver collected from HBV-infected hBMSC-FRGS mice from 0 to 54 w.p.i. 23 
exhibited the typical morphology of cirrhosis, with diffused scars, nodules and a 24 
subsidence area (Figure 6C). Liver tissues from uninfected controls and HBV-infected 25 
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hBMSC-FRGS mice were collected from 0 to 54 w.p.i. for M&T staining. According 1 
to globally accepted criteria [25, 26], liver cirrhosis was observed in 10% (2/20) of the 2 
HBV-infected hBMSC-FRGS mice at 24 w.p.i. and in 55% (11/20) of the mice at 54 3 
w.p.i. (Figure 6D, red column). In contrast, no pathological features of liver cirrhosis 4 
were observed in the uninfected controls (Figure 6D, white column). The M&T 5 
staining results showed that, the progression of liver fibrosis to cirrhosis from 24 to 54 6 
w.p.i. exhibited the typical characteristics, including increased collagenous 7 
accumulation, fibre hyperplasia, an abnormal hepatic lobule structure, platelet 8 
collapse and nodule formation (Figure 6E and Figure S9). IHC staining showed that, 9 
the cirrhotic nodules were positive for HLA. Confluent necrosis with residual 10 
inflammation and scarring varying from mild portal expansion to periportal fibrous 11 
strands and bridging fibrosis with loss of architecture and nodule formation were 12 
observed during this period (Figure 6F). These results demonstrated that, the 13 
progression and characteristics of chronic HBV infection-induced liver cirrhosis in 14 
hBMSC-FRGS mice were similar to the disease pattern observed in CHB patients. 15 
 16 
Discussion 17 
A number of chemical-, diet-, and surgery-based as well as genetically modified 18 
cirrhosis models have been commonly used to elucidate the mechanisms involved in 19 
end-stage liver cirrhosis [27]. However, due to the difficulties associated with 20 
reconstructing the human immune system in animals, few infection-based animal 21 
models have been developed to reflect the natural progression of HBV-induced 22 
cirrhosis [28]. 23 
 24 
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As we and other researchers have reported, hBMSCs have many benefits, including 1 
immune tolerance, easy procurement and potential transdifferentiation into multiple 2 
lineages [14, 15, 29], and the development of dual humanized mouse models through 3 
a single hBMSC transplantation might overcome the above-mentioned limitations [30, 4 
31]. In a recent study, the A2/NSG-hu HSC/Hep mouse model generated with JO2 5 
administration showed significantly higher serum hALB levels and amounts of 6 
hCD45+ cells in blood than the model without JO2 administration [8], suggesting that 7 
JO2-induced FHF is essential to establish high chimerism of both hBMSC-derived 8 
hepatocytes and immune cells. Compared with mild liver injury, which was used in 9 
previous studies, FHF was used in this study because it provides more adequate space 10 
and conditions for supporting hBMSC proliferation and transdifferentiation into 11 
human hepatocytes and multiple immune cell lineages, including myeloid and 12 
lymphoid cells (B cells, T cells, NK cells, macrophages and DCs), and as a result, the 13 
use of this model generated significant chimerism of both human hepatocytes and 14 
syngeneic immune cells in the liver, spleen, peripheral blood, BM, thymus and 15 
mesenteric lymph nodes. Our previous study and others have demonstrated that 16 
hBMSCs can secrete many useful cytokines, including IL3, GMCSF and MCSF, 17 
through paracrine effects [15, 32], and these cytokines might be helpful for improving 18 
the development and maturation of human immune cell lineages. Our model system 19 
involving FHF conditions and a single hBMSC transplantation showed that HBV 20 
infection-based animal models exhibited human immunity could be produced with 21 
high reproducibility. Clarifying the detailed chimerism mechanisms associated with 22 
the cell transdifferentiation or fusion of implanted stem cell into human hepatocytes 23 
and multiple lineages of human immune cells in vivo will be an interesting research 24 
direction [33, 34, 35].  25 
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 1 
Recently, several mouse models, such as A2/NSG-hu HSC/Hep, HIS-Hep FRGN and 2 
HIS-HUHEP mouse, have been demonstrated as promising alternatives for HBV 3 
infection and chronic liver injury through co-transplantation with human foetal or 4 
primary hepatocyte and syngeneic HSCs [8, 9, 10]. However, the permanent human 5 
immune responses and further development of cirrhosis need to be improved. 6 
Moreover, an animal model with HBV infection-based cirrhosis has not yet been 7 
developed. Similar to the findings obtained in our previous large animal studies in 8 
pigs [14, 15], in this study, the implanted hBMSCs rescued mice from life-threatening 9 
FHF, repaired the damaged liver structure and ensured long-term survival for over 60 10 
weeks with significant and persistent dual chimerism of human hepatocytes and 11 
multiple immune cell lineages. Based on this efficient dual chimerism, an almost 12 
life-long (56 weeks) chronic HBV infection course was established in the generated 13 
hBMSC-FRGS mice. A serological analysis of HBV antigens and antibodies 14 
demonstrated sustained viremia and immune response against HBV infection. 15 
Biochemical and cytokine evaluations revealed continuing deterioration of liver 16 
function and persistent increases in the levels of many inflammatory cytokines, which 17 
indicated chronic and severe progression of HBV infection in the recipient animals. 18 
Serological tests and IHC also demonstrated that, HBV-induced liver cirrhosis 19 
spontaneously developed in the hBMSC-FRGS mice, with a 55% occurrence after 54 20 
weeks of persistent HBV infection. The hBMSC-FRGS mice generated in this study 21 
constitute a system to display broad and robust virus-host interactions and 22 
immunopathophysiology during chronic hepatitis and liver cirrhosis progression, 23 
including cellular immune responses, cytokine levels, expression of disease-related 24 
genes, and biochemical and pathological changes in the liver. 25 
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 1 
Clinically, immune and inflammation mechanisms are very complicated and primarily 2 
contribute to the progression and outcome of HBV infection [36, 37]. Our 3 
HBV-infected hBMSC-FRGS mice showed continuous progression to chronic liver 4 
diseases, similar to the pattern observed in CHB patients, and this progression was 5 
particularly noticeable for chronic hepatitis and liver cirrhosis, which might depend 6 
on sustained immune attacks, inflammatory reactions and incomplete repair. However, 7 
our hBMSC-FRGS mice also have some limitations, including an unclear mechanism 8 
regarding the origin of human immune cells and lower HBV antigen-specific antibody 9 
levels during the course of HBV infection. The immunopathogenesis of the recipient’s 10 
response to HBV infection, including human leukocyte chemotaxis, hepatocyte 11 
damage, and chronic HBV or severe progression, also needs to be clarified. Many 12 
factors, including cellular permissiveness to HBV, general immune-mediated 13 
suppression, HBV antigen-specific T cell responses and antibody levels, might impact 14 
the clearance of HBV infection [38]. The decrease in the levels of HBV 15 
antigen-specific antibodies observed with sustained viremia in our system might be 16 
induced by immune tolerance, including increased amounts and proportions of 17 
hFoxp3+hCD4+ regulator T cells (Tregs) and hPD-1+hCD8+ exhausted TC cells [10, 18 
39]. Moreover, the role of each human cell subset and their interactions in the initiation 19 
of liver fibrosis and progression to cirrhosis are very complex and remain unclear in 20 
both CHB patients and animal models with chronic HBV infection [27, 40]. Therefore, 21 
our new model combined with the recently developed mass cytometry technique [41, 22 
42] provides a new platform for investigating these unknown and complex mechanisms. 23 
Further improvements to this dual humanized system of immunocompetent animals 24 
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for HBV, HCV and other hepatotropic viruses will also lead to exciting research 1 
discoveries. 2 
 3 
In summary, we developed a novel dual humanized mouse model with efficient 4 
chimerism of human liver cells and human immune cell lineages using a single 5 
transplantation of hBMSCs, which were sensitive to chronic HBV infection and 6 
generated sustained human immune and inflammatory responses that led to liver 7 
cirrhosis (Figure 7). Our system, which is easily reproduced, constitutes a new animal 8 
model that successfully recapitulates the natural disease progression of HBV infection 9 
and thus opens opportunities for understanding viral immune pathophysiology and 10 
improving the intervention strategies for HBV-related liver diseases. 11 
 12 
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Figure legends 1 
Figure 1. Generation of hBMSC-FRGS mice through the transplantation of 2 
hBMSCs into FHF-FRGS mice. (A) Schematic design of the rescue of FRGS mice 3 
with life-threatening FHF by hBMSC transplantation, the generation of 4 
hBMSC-derived human hepatocytes and immune cell lineages, and the modelling of 5 
the progression of HBV infection-induced viremia, immune and inflammatory 6 
responses, antibody synthesis, chronic hepatitis and liver cirrhosis. (B) Schematic 7 
design of the cell transplantation treatments administered to mice. During the 8 
perioperative period, FHF-FRGS mice with or without hBMSC transplantation 9 
received the same treatments, including NTBC on-off treatment, JO2 and busulfan 10 
injection. FHF-FRGS mice with hBMSC transplantation received a splenic injection 11 
of 1×106 hBMSCs at day 0. The normal FRGS mice were administered 100% NTBC 12 
in their drinking water without any extra treatment. (C) Survival analysis of mice in 13 
the three groups during the perioperative period. The survival of hBMSC-FRGS and 14 
normal FRGS mice was observed for 60 weeks (n=30/group). (D) Temporal changes 15 
in eight typical biochemical markers of liver function (n=8/group). (E) H&E staining 16 
of liver tissue collected from FHF-FRGS with or without hBMSC transplantation and 17 
normal FRGS mice (bar=50 μm). The yellow arrow indicates the haemorrhage point, 18 
the red arrow indicates dead cells, and the black arrow indicates residual cells. (NS, 19 
no significant difference; a, p<0.05; b, p<0.01; c, p<0.001) 20 
 21 
 22 
Figure 2. Characterization of hBMSC-derived hepatocytes in hBMSC-FRGS 23 
mice. (A) Detection of the serum hALB level and percentage of HLA+ cells in the 24 
total population of liver cells (n=8/group). (B) Percentage of hALB+, hNTCP+ and 25 
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hCD45+ cells in the HLA+ cells from week 0 to 60 after hBMSC transplantation 1 
(n=8/group). (C) Correlation analysis between the serum hALB level and the 2 
percentage of hNTCP+ cells in the whole population of liver cells collected from 3 
hBMSC-FRGS mice (n=8/group). (D) Morphology of FACS-sorted hALB+ 4 
hBMSC-Heps at week 12 after transplantation (bar=50 μm). (E) Detection of perfused 5 
hBMSC-Heps by IF staining for hALB and hNTCP at week 12 after transplantation 6 
(bar=50 μm). (F) qRT-PCR analysis of the expression of 19 hepatic genes in the 7 
perfused hBMSC-Heps from week 12 to 60 after transplantation; primary human 8 
hepatocytes and hBMSCs were used as controls (n=6/group). (G) IHC staining of 9 
liver tissues collected from hBMSC-FRGS mice at week 12 after transplantation for 10 
human hepatocyte markers, including hALB, hCK18, hAAT, hFAH and hNTCP 11 
(bar=100 μm). (H) IHC staining for hALB+ hBMSC-Heps in the whole liver lobe 12 
showed multiple distribution patterns, including peri-portal, non- peri-portal, 13 
scatter-like, island-like and cluster-like patterns (bar=1 mm).  14 
 15 
 16 
Figure 3. Characterization of hBMSC-derived multiple immune cell lineages in 17 
hBMSC-FRGS mice. (A) Total number of hCD45+ cells in the peripheral blood, 18 
spleen, liver, BM, thymus, and lymph nodes in hBMSC-FRGS mice (blue circle) and 19 
control FRGS mice (black circle) at week 12 after transplantation (n=8/group). (B) 20 
Detection of human cytokine expression in hCD45+ cells isolated from the livers of 21 
hBMSC-FRGS mice and subjected to in vitro stimulation with PHA (green column) 22 
or PMA/ionomycin (violet column) for 24 hours (n=6/group). hCD45+ cells without 23 
stimulation (black column) were used as controls. (C) Detection of hBMSC-derived 24 
human immune cells in the livers of hBMSC-FRGS mice at 12 weeks after 25 
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transplantation by IHC for B cells (hCD19+), T cells (hCD4+ and hCD8+), NK cells 1 
(hNKp46+), macrophages (hCD86+ and hCD163+) and dendritic cells (hCD11c+ and 2 
hCD123+) (bar=100 μm). (D) Gating scheme and representative FACS contour plots 3 
of hBMSC-derived multiple human immune cell lineages in the livers of 4 
hBMSC-FRGS mice. (E) Reconstitution and maintenance of hCD45+ cells, hCD19+ B 5 
cells, hCD3+ T cells and hCD3-hNKp46+ NK cells in the peripheral blood, spleen and 6 
livers of hBMSC-FRGS mice from week 3 to 60 after transplantation (10 different 7 
donors, n=3). Relative proportions of (F) hCD4+ helper T (TH) cells and hCD8+ 8 
cytotoxic T (TC) cells within the population of hCD45+hCD3+ T cells in the spleen 9 
and liver of hBMSC-FRGS mice (n=6/group); (G) hCD86+ M1 and hCD163+ M2 10 
subset within the population of hCD45+hCD3-hCD14+hCD68+ macrophages in the 11 
spleen and liver of hBMSC-FRGS mice (n=6/group); and (H) hCD11c+ myeloid and 12 
hCD123+ plasmacytoid subsets within the population of 13 
hCD45+hCD3-hCD14-HLA-DR+ DCs in the spleen and liver of hBMSC-FRGS mice 14 
(n=6/group). (U.D., undetectable; a, p<0.05; b, p<0.01; c, p<0.001). 15 
 16 
 17 
Figure 4. Establishment of sustained HBV infection in hBMSC-FRGS mice. (A) 18 
Serum (A) hALB (grey columns), HBV DNA (black lines), (B) HBsAg (grey columns) 19 
and HBeAg (black lines) levels in hBMSC-FRGS mice inoculated with HBV 20 
(genotype C) from 0 to 56 w.p.i. (n=8/group). (C) IHC staining for hALB+, HBsAg+ 21 
and HBcAg+ cells of liver tissues collected from HBV-infected and uninfected 22 
hBMSC-FRGS mice and FRGS mice at 16 w.p.i. (bar=200 μm). (D) Statistical 23 
analysis of IHC images to determine the proportion of HBsAg+ cells in the population 24 
of hALB+ cells from 0 to 56 w.p.i. (n=8/group). (E) FISH analysis for HBV DNA in 25 
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the population of hALB+ cells collected from HBV-infected hBMSC-FRGS mice and 1 
uninfected controls at 4 w.p.i. (bar=20 μm). Detection of intrahepatic HBV cccDNA 2 
levels in HBV-infected hBMSC-FRGS mice from 0 to 56 w.p.i. by (F) southern blot 3 
and (G) qRT-PCR (n=8/group). (H) Analysis of the correlation between the serum 4 
HBV DNA and serum HBsAg levels and the correlation between the serum HBV 5 
DNA and intracellular HBV cccDNA levels (n=10).  6 
 7 
 8 
Figure 5. Chronic HBV infection induced immune and inflammatory responses 9 
and chronic hepatitis in the hBMSC-FRGS mice. (A) Amount of hCD45+ cells (top 10 
left) and percentages of hCD45+hCD3-hNKp46+ NK cells (top right), 11 
hCD45+hCD3-hCD68+ macrophages (bottom left) and hCD45+hCD3+ T cells (bottom 12 
right) in the livers of uninfected controls and HBV-infected hBMSC-FRGS mice from 13 
0 to 48 w.p.i. (n=8/group). (B) Liver sections from uninfected controls (top) and 14 
HBV-infected hBMSC-FRGS mice (bottom) at 24 w.p.i. were co-stained for HBsAg 15 
(red) and hCD68 (green). DAPI-stained nuclei are shown in blue (bar=100 μm). (C) 16 
Plasma sample from uninfected controls and HBV-infected hBMSC-FRGS mice were 17 
analysed by ELISA for various human cytokines (n=8/group). (D) qRT-PCR analysis 18 
for the expression of human cytokine genes in HLA+ liver cells collected from 19 
uninfected controls and HBV-infected hBMSC-FRGS mice (n=4/group). (E) ELISA 20 
for the concentrations of hIgM and hIgG in sera of uninfected controls and 21 
HBV-infected hBMSC-FRGS mice (n=8/group). (F) ELISA for the concentrations of 22 
HBsAb, HBeAb and HBcAb in sera of uninfected controls and HBV-infected 23 
hBMSC-FRGS mice (n=8/group). (G) H&E staining of liver tissues collected from 24 
uninfected controls and HBV-infected hBMSC-FRGS mice. The yellow arrow 25 
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indicates the haemorrhage point, and the black arrow indicates the recruitment and 1 
infiltration of immune cells (bar=50 μm). (NS, no significant difference; a, p<0.05; b, 2 
p<0.01; c, p<0.001). 3 
 4 
 5 
Figure 6. Progression of chronic HBV infection induced liver cirrhosis. (A) 6 
Concentration of the liver cirrhosis markers HA and GGT in serum of uninfected 7 
controls (blue line) and HBV-infected hBMSC-FRGS mice (red line) (n=8/group). (B) 8 
qRT-PCR analysis of the expression of four human cirrhosis-related genes in liver 9 
tissues collected from uninfected controls (white column) and HBV-infected 10 
hBMSC-FRGS mice (red column) (n=8/group). (C) Morphology of liver cirrhosis and 11 
(D) statistical analysis of related morbidity in uninfected controls (white column) and 12 
HBV-infected hBMSC-FRGS mice (red column) during a 54-week HBV infection 13 
course (n=20/group). (E) M&T staining of liver tissues collected from uninfected 14 
controls and HBV-infected hBMSC-FRGS mice during the progression of 15 
HBV-induced liver cirrhosis (bar=500 μm). (F) IHC staining for HLA and 16 
pathological staining (H&E, M&T, SR/FG and V.G.) of serial sections collected from 17 
uninfected controls and HBV-infected hBMSC-FRGS mice with typical liver cirrhosis 18 
(bar=500 μm). (NS, no significant difference; U.D., undetectable; a, p<0.05; b, 19 
p<0.01; c, p<0.001) 20 
 21 
 22 
Figure 7 Progression of chronic HBV infection induced hepatitis and liver 23 
cirrhosis in dual humanized hBMSC-FRGS mice. A novel dual-humanized mouse 24 
model with efficient chimerism of human liver cells and human immune cell lineages 25 
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was developed using a single transplantation of hBMSCs, which were sensitive to 1 
chronic HBV infection and generated sustained human immune and inflammatory 2 
responses that led to liver cirrhosis. 3 
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